Endovascular Therapy Improves Left Ventricular Diastolic Function in HFpEF
FRIDAY, Sept. 20, 2024 -- For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ventricular (LV) diastolic function, according to a study published online Sept. 9 in Circulation: Heart Failure.
Sven Baasen, M.D., from the University Düsseldorf in Germany, and colleagues examined whether EVT of flow-limiting peripheral stenosis improved LV diastolic function among 30 patients with symptomatic peripheral artery disease and HFpEF who were scheduled for EVT or angiography. Patients were examined at baseline, the day after EVT or angiography (25 and five individuals, respectively), and at four-month follow-up.
The researchers observed a significant change in peripheral hemodynamics after EVT, with a decrease in total peripheral resistance and an increase in common femoral artery flow and ankle brachial index. After EVT, there was an improvement in aortic function, with a significantly reduced augmentation index and pulse wave velocity and increased compliance, resulting in a decline in aortic pulsatile load. Compared with control, LV diastolic function improved after EVT, acutely and at follow-up, with increased septal and lateral e' velocities and decreased E/e' and left atrial volume index. At follow-up, there were decreases in LV mass index and LV mean wall thickness. Post-EVT, there was improvement in the New York Heart Association class and treadmill walking distance at follow-up. Independent contributors to E/e' included augmentation index, pulse wave velocity, and arterial compliance.
"Successful endovascular treatment of flow-limiting stenosis in patients with definite HFpEF acutely led to improvement of diastolic function, with a sustained effect at the four-month follow-up," the authors write.
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
First Heart Failure Hospitalization Occurs Earlier for Some Racial, Ethnic Groups
MONDAY, Sept. 8, 2025 -- First heart failure hospitalization occurs at a significantly younger age for non-Hispanic (NH) Asian, NH Black, and Hispanic adults than for NH White...
β-Blockers Not Beneficial After MI Without Reduced Left Ventricular Ejection Fraction
TUESDAY, Sept. 2, 2025 -- For patients with acute myocardial infarction (MI), beta-blockers are not beneficial in those without reduced left ventricular ejection fraction (LVEF)...
Environmental Benefit Seen With GLP-1 Receptor Agonist Use in Heart Failure
FRIDAY, Aug. 29, 2025 -- Patients with heart failure using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have less carbon dioxide equivalent (CO2e) greenhouse gas (GHG)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.